Combination therapy for advanced triple-negative breast cancer
Part of Cancer, Skin clinical trials.
This trial tests a combination of two drugs (sacituzumab tirumotecan and tagitanlimab) for people with advanced triple-negative breast cancer that has progressed after earlier treatments. The goal is to see if this combination can help control the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have triple-negative breast cancer that is advanced, has returned, or has spread to other parts of the body.
- You have already received chemotherapy combined with an immunotherapy drug (PD-1/PD-L1 inhibitor) for your advanced cancer or as part of earlier treatment, and your cancer has progressed.
- Your cancer tests positive for a protein called PD-L1 (with a CPS score of at least 1).
- You have at least one measurable tumor (not just skin or bone lesions).
- You are in generally good health (able to carry out daily activities) and have adequate organ and bone marrow function.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two drugs, sacituzumab govitecan (Sac-TMT) and toripalimab, as a first treatment for women with advanced triple-negative breast cancer that tests positive for a protein called PD-L1. The goal is to see if this combination is safe and effective in shrinking or controlling the cancer.
This study tests a new combination of two targeted drugs for advanced triple-negative breast cancer. It aims to see if the combination can help stop the cancer from growing, and it may be an option if you've already tried standard chemotherapy.
This trial tests a combination of two drugs—sacituzumab govitecan (a targeted chemotherapy) and toripalimab (an immunotherapy)—as the first treatment for advanced triple-negative breast cancer. The goal is to see if this pair works better than standard treatments, and to look for biomarkers that might predict who benefits most.
This trial tests a new drug combination (Trop-2 antibody-drug conjugate plus other therapies) for advanced triple-negative breast cancer that has spread or come back. It may offer a new option for people who have had only 1–2 prior chemotherapies and have not used immunotherapy or anti-angiogenic drugs before.
This trial tests a combination of two drugs—sacituzumab govitecan (a targeted therapy) and Q901 (a study drug that blocks a protein needed for cancer cell growth)—in people with advanced triple-negative breast cancer who have already tried other treatments. The goal is to see if this combination can shrink or control the cancer.
This trial tests a new drug, Sac-TMT, given alone or with an immunotherapy drug (pembrolizumab) for people with advanced triple-negative breast cancer who have not yet received any treatment for advanced disease. The goal is to see if this combination can shrink tumors or slow the cancer's growth.
Hear when a new PD-L1 Positive trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.